BeiGene
BGNE
#991
Rank
S$26.75 B
Marketcap
$241.86
Share price
1.55%
Change (1 day)
-0.57%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of September 2024 : S$7.87 Billion

According to BeiGene 's latest financial reports the company's total assets are S$7.87 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31S$7.66 B-10.35%
2022-12-31S$8.55 B-25.89%
2021-12-31S$11.53 B55.74%
2020-12-31S$7.40 B240.88%
2019-12-31S$2.17 B-29.28%
2018-12-31S$3.07 B119.58%
2017-12-31S$1.39 B138.31%
2016-12-31S$0.58 B255.6%
2015-12-31S$0.16 B133.12%
2014-12-31S$70.85 M373.99%
2013-12-31S$14.94 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
S$24.54 M-99.69%๐Ÿ‡บ๐Ÿ‡ธ USA
S$3.04 B-61.31%๐Ÿ‡บ๐Ÿ‡ธ USA